Pharmacogenomics and Personalized Medicine in the Treatment of Diabetes Program
The Pharmacogenomics and Personalized Medicine in the Treatment of Diabetes Program supports projects that focus on increasing our understanding of the genetic and epigenetic variation that influences the effectiveness and safety of pharmacotherapy for diabetes and related disorders. This program also supports efforts to translate these and other findings into clinical practice and to develop technologies to support these efforts. Areas of interest include, but are not limited to:
a) Use of genetic analysis such as genome-wide association studies, copy-number variation determination, fine-mapping, and functional genomics to identify genes and epigenetic factors that contribute to variable responses to drugs.
b) Studies to understand the contributions and mechanisms of genetic and epigenetic variation, as well as other forms of variation, by examining their functional consequences in the pharmacodynamic and pharmacokinetic responses to and of therapeutic agents.
c) Development of new experimental and computational methodologies, platforms, and models to facilitate the understanding of pharmacologically-relevant genetic and epigenetic variation within populations and individuals.
d) Formation of collaborative relationships between basic scientists, clinicians, geneticists, computational biologists, regulatory affairs experts, and industry to translate discoveries into practical approaches to personalized medicine.
For more information, contact Dr. Aaron Pawlyk, Director, Pharmacogenomics.
Resources for Researchers
Related Study Sections
- Dr. Kristin Abraham, Cell Signaling and Diabetes Centers Program Director
- Dr. Terry Bishop, Hematology Research Programs Director
- Dr. Olivier Blondel, Director, Endocrine Systems Biology Program
- Dr. Arthur Castle, Director, Metabolomics and Informatics Programs
- Dr. Edward Doo, Director of the Liver Diseases Program
- Dr. Judith Fradkin, Director, Division of Diabetes, Endocrinology, and Metabolic Diseases
- Dr. Carol Haft, Senior Advisor for Cell Biology, Associate Director for Grants Administration
- Dr. James Hyde, Senior Advisor, Research Training and Career Development Programs
- Dr. Teresa Jones, Diabetes Complications Program Director
- Dr. Maren Laughlin, Senior Advisor for Integrative Metabolism
- Dr. Saul Malozowski, Senior Advisor for Endocrine Physiology
- Dr. Ronald Margolis, Senior Advisor, Molecular Endocrinology
- Dr. Michael May, Director, Gastrointestinal Neuroendocrinology Program
- Dr. Catherine McKeon, Senior Advisor for Genetic Research in Diabetes, Endocrinology and Metabolic Diseases
- Dr. Aaron Pawlyk, Director, Pharmacogenomics and Drug Discovery Program
- Dr. Sheryl Sato , Director, Neurobiology of Obesity and Developmental Biology
- Dr. Salvatore Sechi, Proteomic Program Director
- Dr. Jose Serrano, Director of the Liver and Biliary Program; Director of the Pancreas Program
- Dr. Corinne Silva, Director, Intracellular and Intrauterine Signaling Programs
- Dr. Myrlene Staten, Senior Advisor, Diabetes Research Translation
- Dr. Daniel Wright, Hematology Research Programs Director
Page last updated: March 20, 2013